ResearcherThe Wistar InstituteNo recent work listed
Abhilasha Purohit
Matched on OpenAlex author ID A5103555905. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 16
2016: 1 paper · 2017: none · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper
Papers 7
- Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2023.216185↗
- Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. Co-author PMID 35141005↗
- Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis. Co-author DOI 10.1016/j.ajpath.2021.01.002↗
- CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. Co-author DOI 10.1096/fj.201902990r↗
- Semaphorin-5A maintains epithelial phenotype of malignant pancreatic cancer cells. First author DOI 10.1186/s12885-018-5204-x↗
- Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. Co-author DOI 10.18632/oncotarget.23644↗
- CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer. Co-author DOI 10.18632/oncotarget.6906↗
Closest collaborators
The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sugandha Saxena · 6 shared papers, 2018–2023 · strength 0.76
- Paper Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. DOI 10.1016/j.canlet.2023.216185↗
- Paper Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis. DOI 10.1016/j.ajpath.2021.01.002↗
- Paper Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. PMID 35141005↗
- Rakesh K. Singh · 6 shared papers, 2016–2023 · strength 0.69
- Paper Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. DOI 10.1016/j.canlet.2023.216185↗
- Paper Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis. DOI 10.1016/j.ajpath.2021.01.002↗
- Paper Semaphorin-5A maintains epithelial phenotype of malignant pancreatic cancer cells. DOI 10.1186/s12885-018-5204-x↗
- Surinder K. Batra · 5 shared papers, 2016–2023 · strength 0.58
- Paper Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. DOI 10.1016/j.canlet.2023.216185↗
- Paper Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. PMID 35141005↗
- Paper CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. DOI 10.1096/fj.201902990r↗
- Dipakkumar R. Prajapati · 4 shared papers, 2020–2023 · strength 0.58
- Paper Small molecule antagonist of CXCR2 and CXCR1 inhibits tumor growth, angiogenesis, and metastasis in pancreatic cancer. DOI 10.1016/j.canlet.2023.216185↗
- Paper Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis. DOI 10.1016/j.ajpath.2021.01.002↗
- Paper Differential expression profile of CXC-receptor-2 ligands as potential biomarkers in pancreatic ductal adenocarcinoma. PMID 35141005↗
- Caitlin Molczyk · 2 shared papers, 2022–2023 · strength 0.33
- Sushil Kumar K · 2 shared papers, 2020–2023 · strength 0.29
- Satyanarayana Rachagani · 3 shared papers, 2016–2020 · strength 0.25
- Paper CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. DOI 10.1096/fj.201902990r↗
- Paper Pathological and functional significance of Semaphorin-5A in pancreatic cancer progression and metastasis. DOI 10.18632/oncotarget.23644↗
- Paper CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer. DOI 10.18632/oncotarget.6906↗
- Pranita Atri · 2 shared papers, 2018–2022 · strength 0.22
- Reegan Sturgeon · 1 shared paper, 2023 · strength 0.18
- Mohammad I. Awaji · 2 shared papers, 2018–2020 · strength 0.18
- Rakesh K. Singh · 1 shared paper, 2022 · strength 0.14
- Michael Anthony Hollingsworth · 1 shared paper, 2022 · strength 0.14
- Paul M. Grandgenett · 1 shared paper, 2022 · strength 0.14
- Sukhwinder Kaur · 1 shared paper, 2022 · strength 0.14
- Maneesh Jain · 1 shared paper, 2020 · strength 0.10
- Michel M. Ouellette · 1 shared paper, 2016 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.